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ABSTRACT
Structured secondary preventions programs, called fracture liaison services (FLSs), increase the rate of evaluation with bone densi-
tometry and use of osteoporosis medication after fracture. However, the evidence regarding the effect on the risk of recurrent frac-
ture is insufficient. The aim of this study was to investigate if implementation of FLS was associated with reduced risk of recurrent
fractures. In this retrospective cohort study, electronic health records during 2012 to 2017 were used to identify a total of 21,083
patients from four hospitals in Western Sweden, two with FLS (n = 15,449) and two without (n = 5634). All patients aged 50 years
or older (mean age 73.9 [SD 12.4] years, 76% women) with a major osteoporotic index fracture (hip, clinical spine, humerus, radius,
and pelvis) were included. The primary outcome was recurrent major osteoporotic fracture. All patients with an index fracture during
the FLS period (n = 13,946) were compared with all patients in the period before FLS implementation (n = 7137) in an intention-to-
treat analysis. Time periods corresponding to the FLS hospitals were used for the non-FLS hospitals. In the hospitals with FLSs, there
were 1247 recurrent fractures during a median follow-up time of 2.2 years (range 0–6 years). In an unadjusted Cox model, the risk of
recurrent fracture was 18% lower in the FLS period compared with the control period (hazard ratio = 0.82, 95% confidence interval
[CI] 0.73–0.92, p = .001), corresponding to a 3-year number needed to screen of 61, and did not change after adjustment for clinical
risk factors. In the hospitals without FLSs, no change in recurrent fracture rate was observed. Treatment decisions were made accord-
ing to the Swedish treatment guidelines. In conclusion, implementation of FLS was associated with a reduced risk of recurrent frac-
ture, indicating that FLSs should be included routinely at hospitals treating fracture patients. © 2020 The Authors. Journal of Bone and
Mineral Research published by American Society for Bone and Mineral Research.
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Introduction
Fractures, especially hip and vertebral fractures, increase suf-fering, morbidity, and mortality at high societal and health
care costs.(1) At the age of 50 years, the lifetime risk of sustaining
a fragility fracture is 50% for women and 20% for men.(2) The risk
of recurrent fracture is most pronounced and increased up to
five times in the first 2 years after an index fracture.(3,4) Osteopo-
rosis medications such as oral and intravenous bisphosphonates,
denosumab, and teriparatide are effective in increasing bone
mineral density (BMD) and reduce fracture risk by approximately
40% for hip fractures and by 45% to 70% for vertebral fractures.(5)
Despite the proven efficacy of these treatments, the probability
to receive osteoporosis medication in the US within a year after
hip fracture has declined rapidly from 40.2% in 2002 to 20.5%
in 2011.(6)
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To increase osteoporosis medication treatment rates after
fracture, structured secondary prevention programs called frac-
ture liaison services (FLSs) have been implemented worldwide.(7)
Patients receiving fracture care within an FLS have higher rates
of BMD testing, treatment initiation, and better adherence.(8,9)
However, the evidence regarding FLS and association with
reduced risk of recurrent fracture is insufficient, consisting of
smaller studies, studies with short follow-up time, and studies
with high risk of various biases.(8–13)
The primary objective of the present study was to investigate
if FLS implementation was associated with reduced risk of recur-
rent fracture, using data from four hospitals in Western Sweden,
two with FLSs and two without. Secondary objectives included
to investigate the associations between FLS implementation
and osteoporosis medication use, fall injuries, and mortality.
Materials and Methods
Study design
This register-based cohort study used hospital electronic patient
records in Western Sweden to identify all patients aged 50 years
or older with a major osteoporotic fracture (fracture of the wrist,
upper arm, hip, vertebra, or pelvis) during 2012 to 2017. All
patients with amajor osteoporotic fracture during the FLS period
were compared with all patients with a major osteoporotic frac-
ture before the FLS implementation. The risk of recurrent frac-
ture was investigated using multivariable Cox models. The FLS
hospitals and non-FLS hospitals were analyzed separately, using
the same methodology. The study was approved by the regional
ethical review board in Gothenburg.
Fracture liaison services
Skaraborg Hospital, a regional hospital serving 265,000 inhabi-
tants, started an FLS on January 1, 2013, and included all patients
aged 50 years or older seeking care for amajor osteoporotic frac-
ture. All medical secretaries at the emergency and orthopedic
departments were instructed to refer patients for a fracture risk
assessment, using FRAX,(14) and bone densitometry with dual-
energy X-ray absorptiometry (DXA), which were later analyzed
by a specialist who sent a treatment recommendation directly
to the primary care physician. Starting January 1, 2014, all
patients aged 80 years or older with a hip fracture were offered
parenteral osteoporosis treatment (zoledronic acid [iv] or denu-
sumab [sc]) in their homes, without prior DXA. A detailed
description and evaluation of the first 2 years of this FLS has
been described previously.(11)
The Sahlgrenska University Hospital, which serves 715,000
inhabitants in the Gothenburg region, started a similar FLS on
July 1, 2014. Patients with major osteoporotic fractures were
identified in three ways. First, a coordinator assessed data
extracts from the Swedish Fracture Register(15) and excluded
malignancies and obvious high-energy fracture events. Second,
the radiology department identified and referred vertebral frac-
ture patients to the coordinator. And third, admitted patients
with vertebral or hip fractures were offered parenteral osteopo-
rosis treatment without DXA examination before leaving the hos-
pital. The coordinator selected patients for FRAX and DXA
examination, which were analyzed by a specialist who sent a
treatment recommendation directly to the primary care
physician.
At both FLS hospitals, treatment decisions were based on the
Swedish treatment guidelines, ie, to consider treatment for
patients with (i) previous hip or spine fracture; (ii) other (than
hip or spine) previous fracture, a low BMD (T-score ≤ −2.0 SD),
and FRAX-score ≥ 20% for major osteoporotic fracture;
(iii) osteoporosis diagnosis; or (iv) 5 mg of daily oral glucocorti-
coid treatment for 3 months or more.
Södra Älvsborgs Hospital, a county hospital, serving approxi-
mately 201,000 inhabitants within and around the city of Borås,
as well as Alingsås Hospital, serving approximately 102,000
inhabitants, did not implement FLSs at any time during the study
period. However, in order to study possible temporal trends in
the rate of recurrent fracture, we assumed that FLS implementa-
tion had occurred for major osteoporotic fractures on the same
date as the nearby Sahlgrenska University Hospital (July
1, 2014), thus enabling a comparison of the same time periods
as the FLS hospitals.
Ascertainment of fracture
All hospital-based nonmalignant fracture diagnoses in ICD-10
regardless of type of trauma were collected, apart from head
fractures. Refinement of the fracture data was performed in sev-
eral steps. First, if there was a simultaneous code indicating
revisit (Z09, Z47, Z48), that fracture diagnosis was discarded. Sec-
ond, hip fracture diagnoses (cervical S72.0, trochanteric S72.1, or
subtrochanteric S72.2) without a simultaneous code for surgical
procedure (NFB, NFC, or NFJ) were discarded. Identification of
hip fracture in registers using this combination has high accu-
racy.(16) Third, a washout period of 5 months was used, ie, if a
fracture diagnosis on the same skeletal site was repeated within
5 months, the latter diagnosis was excluded. The washout period
length has been defined using an X-ray-verified data set in order
to maximize accuracy.(11) Finally, in both the pre-FLS and in the
FLS period, the first major osteoporosis fracture was designated
index fracture and used as baseline. Any subsequent major oste-
oporotic fracture or hip fracture was considered a recurrent frac-
ture. Recurrent fractures occurring at different hospitals than the
hospital of the index fracture were also accounted for. Time to
recurrent fracture was censored for moving out of the region,
death, or end of study period (December 31, 2017).
Ascertainment of nonskeletal fall injury and death
Using electronic health records from hospitals and primary care,
a fall (W00-W19) on the same date as an injury (S00-T14) on an
occasion without a fracture (Sx2, T02, T08, T10, T12) was classi-
fied as nonskeletal fall injury. Time to such nonskeletal fall injury
was also censored for moving out of the region, death, or end of
study period (December 31, 2017). Time to death was also cen-
sored for moving out of the region or end of study period.
Ascertainment of medical history
Using diagnoses from hospitals and primary care, a 1-year his-
toric window was used to assess both previous medication and
previous illnesses, thus including 2011 (Table 1). The regional
prescription register was used to identify calcium and vitamin
D treatment and osteoporosis medication. To identify nonpre-
scribed parenteral treatment offered to patients at outpatient
clinics or while admitted, the combination of an osteoporosis
diagnosis (M8) and a code for intravenous (DT016) or subcutane-
ous (DT021) administration was used. Charlson comorbidity
index was calculated to summarize and quantify comorbidity.(17)
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Statistical analyses
To assess differences in baseline characteristics, standardized dif-
ferences were calculated.(18) For a given covariate, a standard-
ized difference of less than 10% indicates a relatively small
imbalance.(18) Confidence intervals for event rates were calcu-
lated assuming Poisson distributions. To investigate the
association between participation in FLS and recurrent fracture
risk, a Cox proportional hazards model starting at baseline was
used. In contrast to logistic regression, the Cox regression model
uses the length of each individual’s follow-up period. Cox ana-
lyses were performed for major osteoporotic fracture, hip frac-
ture, nonskeletal fall injury, and death. The multivariable Cox
model was adjusted for age, sex, type of index fracture, any
Table 1. Characteristics of Patients With Index Major Osteoporotic Fracture During Versus Before the FLS Period, in Hospitals With and
Without FLS
A. Hospitals with FLS B. Hospitals without FLS
Before FLS During FLS St. Diff1 “Before” FLS “During” FLS St. Diff.1
n = 4828 n = 10,621 (%) n = 2309 n = 3325 (%)
Female sex, n (%) 3677 (76.2%) 8128 (76.5%) 0.9 1760 (76.2%) 2521 (75.8%) 0.9
Age (years), mean (SD) 74.2 (12.6) 73.7 (12.4) 3.7 73.7 (12.2) 74.3 (12.1) 4.3
50–67, n (%) 1638 (33.9%) 3548 (33.4%) 1.1 786 (34.0%) 1018 (30.6%) 7.3
68–81, n (%) 1496 (31.0%) 3638 (34.3%) 7.0 801 (34.7%) 1209 (36.4%) 3.5
82–105, n (%) 1694 (35.1%) 3435 (32.3%) 5.8 722 (31.3%) 1098 (33.0%) 3.8
Index fracture site, n (%)
Wrist (S52.5, S52.6) 1934 (40.1%) 4519 (42.5%) 5.1 1034 (44.8%) 1387 (41.7%) 6.2
Shoulder (S42.2) 1171 (24.3%) 2491 (23.5%) 1.9 527 (22.8%) 729 (21.9%) 2.2
Hip (S72.0-S72.2) 395 (8.2%) 697 (6.6%) 6.2 150 (6.5%) 242 (7.3%) 3.1
Vertebra (S22.0, S22.1, S32.0, M48.5) 666 (13.8%) 1530 (14.4%) 1.8 308 (13.3%) 502 (15.1%) 5.0
Pelvis (S32.4, S32.5, S32.7, S32.8) 662 (13.7%) 1384 (13.0%) 2.0 290 (12.6%) 465 (14.0%) 4.2
Any previous fracture (before index), n (%) 174 (3.6%) 346 (3.3%) 1.9 88 (3.8%) 114 (3.4%) 2.0
Nonskeletal fall injury (before index), n (%) 294 (6.1%) 644 (6.1%) 0.1 137 (5.9%) 212 (6.4%) 1.8
Osteoporosis medication (before index), n (%) 427 (8.8%) 872 (8.2%) 2.3 141 (6.1%) 193 (5.8%) 1.3
Of which peroral bisphosphonates, n (%) 393 (8.1%) 717 (6.8%) 5.3 139 (6.0%) 173 (5.2%) 3.5
Calcium and vitamin D, n (%) 956 (19.8%) 1942 (18.3%) 3.9 364 (15.8%) 512 (15.4%) 1.0
Alcohol-related diseases, n (%) 154 (3.2%) 282 (2.7%) 3.2 58 (2.5%) 62 (1.9%) 4.4
Rheumatoid arthritis, n (%) 51 (1.1%) 142 (1.3%) 2.6 11 (0.5%) 30 (0.9%) 5.1
Osteoporosis diagnosis, n (%) 155 (3.2%) 214 (2.0%) 7.5 40 (1.7%) 49 (1.5%) 2.1
Secondary osteoporosis,2 n (%) 133 (2.8%) 276 (2.6%) 1.0 58 (2.5%) 67 (2.0%) 3.3
Charlson Comorbidity Index, mean (SD) 1.05 (1.54) 1 (1.56) 3.6 0.97 (1.47) 1.08 (1.69) 7.0
=0, n (%) 2490 (51.6%) 5765 (54.3%) 5.4 1252 (54.2%) 1764 (53.1%) 2.3
=1, n (%) 1016 (21.0%) 2129 (20.0%) 2.5 443 (19.2%) 640 (19.2%) 0.2
≥2, n (%) 1322 (27.4%) 2727 (25.7%) 3.9 614 (26.6%) 921 (27.7%) 2.5
Charlson comorbidity index components:
Dementia, n (%) 411 (8.5%) 786 (7.4%) 4.1 164 (7.1%) 242 (7.3%) 0.7
Ischeamic heart disease, n (%) 647 (13.4%) 1131 (10.6%) 8.5 255 (11%) 372 (11.2%) 0.5
Heart failure, n (%) 451 (9.3%) 899 (8.5%) 3.1 203 (8.8%) 289 (8.7%) 0.4
Cerebrovascular disease, n (%) 474 (9.8%) 870 (8.2%) 5.7 207 (9.0%) 311 (9.4%) 1.3
Vascular diseases, n (%) 163 (3.4%) 314 (3.0%) 2.4 62 (2.7%) 97 (2.9%) 1.4
Chronic pulmonary diseases, n (%) 566 (11.7%) 1065 (10.0%) 5.4 248 (10.7%) 346 (10.4%) 1.1
Chronic liver disease, n (%) 48 (1.0%) 118 (1.1%) 1.1 23 (1.0%) 19 (0.6%) 4.8
Tumor without metastasis, n (%) 422 (8.7%) 878 (8.3%) 1.7 216 (9.4%) 324 (9.7%) 1.3
Lymphoma or leukemia, n (%) 46 (1.0%) 119 (1.1%) 1.7 12 (0.5%) 26 (0.8%) 3.3
Diabetes, n (%) 596 (12.3%) 1350 (12.7%) 1.1 289 (12.5%) 429 (12.9%) 1.2
With end organ damage, n (%) 140 (2.9%) 400 (3.8%) 4.8 47 (2.0%) 136 (4.1%) 11.9
Kidney disease, n (%) 154 (3.2%) 368 (3.5%) 1.5 68 (2.9%) 180 (5.4%) 12.4
Moderate or severe, n (%) 33 (0.7%) 119 (1.1%) 4.6 13 (0.6%) 54 (1.6%) 10.2
Hemiplegia, n (%) 22 (0.5%) 77 (0.7%) 3.5 6 (0.3%) 12 (0.4%) 1.8
Peptic ulcer disease, n (%) 52 (1.1%) 100 (0.9%) 1.4 21 (0.9%) 32 (1.0%) 0.5
Metastatic solid tumor, n (%) 52 (1.1%) 136 (1.3%) 1.9 25 (1.1%) 55 (1.7%) 4.9
Patient characteristics at baseline, ie, the time of index fracture, the starting point of the FLS. All medical history data have a 1-year historic window from
baseline. ATC and ICD codes as well as Charlson comorbidity weights are specified in Supplemental Table SS1.
1 St. Diff. = standardized difference = jmean1-mean2j/√(σ12 + σ22)/2), St. Diff. < 10% indicate relatively small imbalances.
2 Secondary osteoporosis includes insulin-dependent diabetes mellitus, hyperparathyroidism, hyperthyroidism, hypogonadism, malnutrition, osteo-
genesis imperfecta, or chronic liver disease.
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previous fracture, previous nonskeletal fall injury, osteoporosis
diagnosis, secondary osteoporosis, rheumatoid arthritis, osteo-
porosis medication, calcium and vitamin D, alcohol-related dis-
eases, and Charlson comorbidity index. For the main outcome,
major osteoporotic fracture, interactions between FLS participa-
tion and sex, tertile of age, and Charlson (ordinal) were tested,
respectively. Subgroup analyses were also performed per sex,
tertile of age, and Charlson stratum (0, 1, ≥2), as well as separated
by hospital. The Cox assumption of proportional hazards was
tested using a time-dependent Cox model with a linear interac-
tion term between time and FLS group. To investigate if the dif-
ference in follow-up time between the groups affected the
result, a sensitivity analysis was performed censoring the Cox
model at 2 years. Competing risk regression analysis was per-
formed using the subdistribution hazard function developed
by Fine and Gray.(19) Incident rates of recurrent fracture were cal-
culated per year of recurrence for the non-FLS hospitals to show
secular trend. A Cox model stratified by hospital (all four hospi-
tals) and including date of index fracture and FLS-indicator
(1/0), was used to determine if there was a secular trend, which
could influence the association between FLS and recurrent frac-
ture. For treatment-naïve patients, adherence to osteoporosis
medication was calculated per year since initiation as total time
with treatment divided by total follow-up time. Statistical ana-
lyses were performed using IBM (Armonk, NY, USA) SPSS soft-
ware, version 22, and Stata version SE 16.0 for Mac (StataCorp,
College Station, TX, USA). Significance testing was two-sided
and a p value less than 0.05 was considered significant.
Analyses to address potential bias
Potential selection bias was addressed in three ways. First,
known risk factors for fracture and morbidity were examined at
the time for index fracture and no clinically relevant differences
between groups should be expected. Second, the Cox hazard
Table 2. Risk of Recurrent Fracture After Major Osteoporotic Index Fracture
A. Hospitals with FLS B. Hospitals without FLS
Before FLS During FLS p Value “Before” FLS “During” FLS p Value
No. of patients with index fractures, n n = 4828 n = 10,621 n = 2309 n = 3325
Time at risk, median (range min-max),
years
4.32 (0–6) 1.70 (0–5) 4.36 (0–6) 1.48 (0–3.50)
Major osteoporotic fracture
No. (%) 621 (12.9) 626 (5.9) 299 (12.9) 214 (6.4)
Per 1000 person-years (95% CI) 35.8 (33.0–38.7) 33.7 (31.1–36.5) 35.1 (31.3–39.4) 43.6 (37.9–49.8)
Unadjusted HR (95% CI) 1 (Reference) 0.82 (0.73–0.92) .001 1 (Reference) 1.10 (0.91–1.33) .34
HR adjusted for age and sex (95% CI) 1 (Reference) 0.82 (0.73–0.92) .001 1 (Reference) 1.08 (0.89–1.30) .45
Multivariable1 adjusted HR (95% CI) 1 (Reference) 0.83 (0.73–0.93) .001 1 (Reference) 1.08 (0.89–1.30) .46
3-year multivariable1 adjusted ARR Reference 1.7 .001
5-year multivariable1 adjusted ARR Reference 2.5 .001
3-year multivariable1 adjusted NNS Reference 61 .001
5-year multivariable1 adjusted NNS Reference 40 .001
Hip fracture
No. (%) 66 (1.4) 74 (0.7) 28 (1.2) 22 (0.7)
Per 1000 person-years (95% CI) 3.6 (2.7–4.5) 3.8 (3.0–4.8) 3.1 (2.0–4.5) 4.3 (2.7–6.5)
Unadjusted HR (95% CI) 1 (Reference) 0.79 (0.56–1.12) .18 1 (Reference) 1.07 (0.58–1.94) .84
HR adjusted for age and sex (95% CI) 1 (Reference) 0.80 (0.56–1.13) .20 1 (Reference) 1.02 (0.56–1.87) .94
Multivariablea adjusted HR (95% CI) 1 (Reference) 0.82 (0.58–1.15) .25 1 (Reference) 0.98 (0.54–1.79) .94
1 Multivariable = age, sex, type of index fracture, previous fracture, previous fall injury, osteoporosis diagnosis, secondary osteoporosis, rheumatoid
arthritis, osteoporosis medication, calcium/vitamin D, alcohol-related diseases, and Charlson comorbidity index.
Fig. 1. Cumulative hazard of recurrent fracture with FLS compared with
the period before the FLS at the two FLS hospitals. The Cox regression
model was adjusted for age, sex, type of index fracture (wrist, humerus,
hip, vertebral, pelvic), any previous fracture, previous nonskeletal fall
injury, osteoporosis diagnosis, secondary osteoporosis, rheumatoid
arthritis, osteoporosis medication, calcium and vitamin D supplementa-
tion, alcohol-related diseases, and Charlson comorbidity index. Medical
history is derived using a 1-year window in the registers. Recurrent frac-
ture includes wrist, humerus, hip, vertebral, and pelvic fractures. The inset
shows the same data on an enlarged y-axis.
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models were adjusted for known risk factors for fracture and
Charlson comorbidity index, where the adjustment was not
expected to change the association. Third, the risk to suffer a
nonskeletal fall injury was investigated, and equal risks of falls
would be expected, if frailty was similar in the compared groups.
Finally, to account for possible temporal bias, ie, changes in
recurrent fracture rate due to time passing, two nearby hospitals
in which no FLS implementation had occurred were analyzed,
using both the multivariable Cox model and incident rates of
recurrent fracture per year. Also, in a sensitivity analysis, the
follow-up timewas censored at 2 years to assess whether the dif-
ference in follow-up time between the two groups affected the
result.
Role of the funding sources
This study was funded by the Swedish Research Council (VR) and
ALF/LUA grants from the Sahlgrenska University Hospital. The
funding sources had no role in the study design; in the collection,
analysis, and interpretation of data; in the writing of the report;
nor in the decision to submit the paper for publication.
Results
The present study included 21,083 patients with index fracture,
with a total follow-up time of 52,429 patient years. The FLS hos-
pitals included 4828 patients followed a total of 18,701 years
before FLS implementation and 10,621 patients who were
included in the FLS period and followed a total of 19,411 years.
The two reference hospitals without FLSs included 2309 patients
before the assumed FLS implementation and were followed a
total of 9138 years, whereas 3325 patients with an assumed
FLS were followed a total of 5143 years. Thus, because of the
study design, patients before the FLS were fewer and had longer
follow-up time than the patients included during the FLS
periods.
Baseline characteristics (at the time of index fracture) were
similar between patients included before and during the FLSs
in both the FLS hospitals (Table 1A) and the non-FLS hospitals
(Table 1B). All standardized differences were less than 10%
(Table 1). A comparison of the FLS hospitals and the reference
hospitals, pre-/post-FLS periods combined, showed similar base-
line characteristics. The use of osteoporosis medication at base-
line was slightly higher in the FLS hospitals (8.4% versus 5.9%).
This was also true for calcium and vitamin D supplementation
(18.8% versus 15.5%), but all standardized differences between
the hospitals were lower than 10% (Supplemental Table S2).
FLS implementation was associated with reduced risk of
recurrent fracture
In the FLS hospitals, using a Cox proportional hazards model, the
risk of recurrent major osteoporotic fracture was 18% lower in
the FLS period comparedwith the period before implementation
(HR = 0.82, 95% CI 0.73–0.93, p < .001). The result was not
affected by multivariable adjustment (Table 2A; Fig. 1), nor by
early censoring after 2 years of follow-up (HR = 0.83, 95% CI
0.73–0.95, p = .008). When applying Fine and Grays’s competing
risk of death regression to the multivariate model, the associa-
tion remained, with a subdistribution hazard ratio of 0.73 (95%
CI 0.66–0.82, p < .001). Using the multivariable-adjusted Cox
model, the 3-year and 5-year number needed to screen (NNS)
Fig. 2. Proportion (%) of patients receiving treatment with osteoporosis medication within 1 year of index fracture at hospitals with FLSs (A) and without
FLSs (B).
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were 61 and 40, respectively (Table 2A). A conservative post hoc
statistical power calculation using the smallest group size
(n = 4828), the incidence of the FLS group (5.9%), the HR of the
Cox model (0.82), and an alpha value of 0.05 yields a power of
95%. While not significant, the risk of hip fracture was also lower
(Table 2A) in the FLS period than in the period before. In the non-
FLS hospitals, no significant associations were found between
the period before and during the assumed FLS for recurrent frac-
ture (Table 2B). There was no apparent secular trend in recurrent
fracture incident rate in the two non-FLS hospitals (Supplemental
Fig. SS1). In a multivariable-adjusted Cox regression using data
from all four hospitals, with stratification by hospital and added
adjustment for index date, the association between FLS imple-
mentation and risk of recurrent fracture was maintained
(HR = 0.82, 95% CI 0.70–0.97, p = .02) and index date was not sig-
nificantly associated with recurrent fracture (p = .96).
Treatment rates after index fracture
In the FLS hospitals, osteoporosis medication treatment rates
within 1 year after index fracture increased significantly from
14.7% to 28.0% (p < .001) after FLS implementation, and the pro-
portion of parenteral treatment increased from 11.8% to 18.9%.
In the hospitals without FLSs, there were no significant changes
in treatment rates before (13.3%) versus after (12.9%), p = .73,
the assumed FLS implementation. Osteoporosis medication
treatment rates after fracture did not differ between the FLS
(14.7% versus 13.3%, p = .10) and non-FLS hospitals before FLS
implementation, whereas after FLS implementation a larger
proportion of fracture patients were treated at the FLS hospitals
than at the non-FLS hospitals (28.0% versus 12.9%, p < .001)
(Fig. 2). In a Cox proportional hazards model with osteoporosis
medication as endpoint, the chance of receiving osteoporosis
medication in the FLS hospitals was 65% higher in the FLS period
than in the period before the FLS (HR = 1.65, 95% CI 1.54–1.78,
p < .001), a result that was not affected by multivariable adjust-
ment (Table 3A). In the non-FLS hospitals, no significant associa-
tion was found (Table 3B). Both FLS and non-FLS hospitals
demonstrated similar patterns of adherence (Supplemental
Fig. S2).
Nonskeletal fall injury and mortality
In the FLS hospitals, both unadjusted and adjusted Cox models
revealed that there was no association between incident nonske-
letal fall injury and FLS implementation (unadjusted HR = 1.02,
95% CI 0.93–1.13, p = .68; Table 3A). FLS implementation was
not significantly associated with mortality (HR = 0.94, 95% CI
0.88–1.01, p = .11; Table 3A). In the non-FLS hospitals, assumed
FLS implementation was not significantly associated with non-
skeletal fall-injury or death (Table 3B).
Association between FLS implementation and recurrent
fracture per hospital
The associations between recurrent risk ofmajor osteoporotic frac-
ture and FLS remained when analyzed per FLS hospital: Skaraborg
Table 3. Chance of Osteoporosis Medication and Risk of Nonskeletal Fall Injury and Death after Major Osteoporotic Index Fracture
A. Hospitals with FLS B. Hospitals without FLS
Before FLS During FLS p Value “Before” FLS “During” FLS p value
No. of patients with index fractures, n n = 4828 n = 10,621 n = 2309 n = 3325
Time at risk, median (range min-max),
years
4.32 (0–6) 1.70 (0–5) 4.36 (0–6) 1.48 (0–3.5)
Osteoporosis medication treatment
initiation
No. (%) 1107 (22.9) 2820 (26.6) 380 (16.5) 414 (12.5)
Per 1000 person-years (95% CI) 72.8 (68.5–77.2) 199.6 (192.3–207.1) 48.7 (43.9–53.9) 91.3 (82.7–100.5)
Unadjusted HR (95% CI) 1 (Reference) 1.65 (1.54–1.78) <.001 1 (Reference) 0.99 (0.86–1.14) .85
HR adjusted for age and sex (95% CI) 1 (Reference) 1.67 (1.55–1.80) <.001 1 (Reference) 0.98 (0.85–1.13) .78
Multivariable1 adjusted HR (95% CI) 1 (Reference) 1.62 (1.51–1.75) <.001 1 (Reference) 1.02 (0.89–1.18) .74
Nonskeletal fall injury
No. (%) 801 (16.6) 1019 (9.6) 379 (16.4) 288 (8.7)
Per 1000 person-years (95% CI) 47.4 (44.1–50.8) 56.6 (53.2–60.2) 45.8 (41.3–50.7) 59.8 (53.1–67.2)
Unadjusted HR (95% CI) 1 (Reference) 1.02 (0.93–1.13) .68 1 (Reference) 1.08 (0.91–1.27) .39
HR adjusted for age and sex (95% CI) 1 (Reference) 1.02 (0.93–1.13) .64 1 (Reference) 1.06 (0.90–1.25) .51
HR adjusted for age, sex, previous fall
injury and Charlson comorbidity
index (95% CI)
1 (Reference) 1.02 (0.93–1.13) .69 1 (Reference) 1.06 (0.90–1.25) .49
Death
No. (%) 1701 (35.2) 1832 (17.2) 701 (30.4) 527 (15.8)
Per 1000 person-years (95% CI) 91 (86.7–95.4) 94.4 (90.1–98.8) 76.7 (71.1–82.6) 102.5 (93.9–111.6)
Unadjusted HR (95% CI) 1 (Reference) 0.94 (0.88–1.01) .11 1 (Reference) 1.21 (1.06–1.37) .003
HR adjusted for age and sex (95% CI) 1 (Reference) 0.96 (0.89–1.03) .23 1 (Reference) 1.14 (1.00–1.29) .04
HR adjusted for age, sex and Charlson
comorbidity index (95% CI)
1 (Reference) 0.96 (0.90–1.03) .30 1 (Reference) 1.09 (0.97–1.24) .16
1 Multivariable = age, sex, type of index fracture, previous fracture, previous fall injury, osteoporosis diagnosis, secondary osteoporosis, rheumatoid
arthritis, osteoporosis medication, calcium/vitamin D, alcohol-related diseases and Charlson comorbidity index.
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HR = 0.75, 95% CI 0.61–0.93, p = .008, and Sahlgrenska HR = 0.84,
95% CI 0.73–0.98, p = .03, respectively (Supplemental Table S3).
Interactions and stratification by age, Charlson
comorbidity index, and sex
In the FLS hospitals, using a multivariable-adjusted Cox analysis,
there were no significant interactions between FLS implementa-
tion and sex (p = .23), Charlson comorbidity index (p = .12), and
age (p = .15), respectively. For the highest tertile of age (82 to
105 years), FLS implementation was associated with a 26% sig-
nificant risk reduction of recurrent fracture with a number
needed to screen of 23 (3 years) and 16 (5 years). Subgroup anal-
ysis per tertile of Charlson comorbidity index, age, and sex are
presented in Supplemental Tables S4–S6.
Discussion
In the present study, we found that patients with a major osteo-
porotic fracture at two Swedish hospitals during an FLS period
had 18% reduced risk of recurrent fracture compared with
patients in the period before the FLS implementation. The risk
of recurrent fracture did not change during the same time period
at two non-FLS hospitals examined. Treatment rates with osteo-
porosis medication increased by 65% and FLS implementation
was not associated with an increased risk of nonskeletal fall
injury, indicating that the reduced risk of recurrent fracture
may be due to an effect of increased use of osteoporosis
medication.
Because age is an important factor for absolute risk of fracture,
we sought to investigate whether age had an impact on the
association between FLS implementation and risk of recurrent
fracture. In subgroup analysis, the association only remained sig-
nificant among the oldest tertile (aged 82 to 105 years). How-
ever, no significant interaction between FLS and age was
observed and the study was not adequately powered for sub-
group analysis. In particular, few cases of recurrent fractures were
observed among the younger patients due to the low absolute
risk and the short follow-up time. We therefore caution against
drawing conclusions regarding lack of efficacy among the youn-
ger patients.
Comparing our study to other studies on recurrent fracture
after FLS implementation, the 18% reduced risk reported herein
is very similar to the 20% reduction reported by Sietsema in a
study of 1312 FLS patients compared with 1312 well-matched
controls. However, a post hoc power analysis suggests that the
study was underpowered.(12) Dell and colleagues implemented
a comprehensive program to screen for osteoporosis, also
including other risk groups than prior fracture, and reported a
37% average reduction in actual hip fracture rate compared with
pre-program historic controls.(20) Huntjens and colleagues found
a 56% reduced risk of recurrent fracture after following 1412
patients for 2 years, only using a different hospital as control,
without reporting baseline characteristics such as risk factors,
previous osteoporosis medication, and comorbidities.(10) Goltz
studied the risk of recurrent fracture in an FLS for 2455 patients
with manifest osteoporosis and compared with matched con-
trols not enrolled in the FLS program.(13) No association with
recurrent risk was found; however, only scarce information on
baseline characteristics were provided.(13) Axelsson and col-
leagues had insufficient follow-up time to investigate risk of
recurrent fracture.(11) Other studies were substantially under-
powered.(9) In contrast to previous studies, we used historic
controls from the same hospital and controlled thoroughly for
baseline characteristics in the analyses. However, a study design
using historic controls could be limited and biased if there are
temporal trends present. Therefore, we performed analysis to
check for any temporal trends. This analysis did not provide
any evidence for temporal trends in the rate of recurrent fracture,
indicating that the lower recurrent fracture risk observed in the
FLS period is due to the FLS implementation itself.
In an effort to assess if the obtained results regarding themag-
nitude of association between FLS implementation and risk of
recurrent fracture presented herein are reasonable, the effect
observed in randomized placebo-controlled trials of the osteo-
porosis medications taken in this study should be considered.
In patients with prior fracture, alendronate treatment reduces
the risk of spine and hip fracture by 45% and 53%, respec-
tively.(21) Since only a proportion of patients in the FLS period will
be eligible and receive osteoporosis medication, the herein
observed 18% reduction in recurrent fracture appears reason-
ably probable.
The study has limitations. First, the observational design pre-
vents assessment of causality. Second, the fracture definitions
were based on register data, without guarantees that all frac-
tures were X-ray verified. However, available electronic health
records enabled us to conduct a large study with the samemeth-
odology, including fracture definitions, for both the FLS and non-
FLS hospitals and for the FLS and non-FLS periods. Third, the
patients before the FLS were fewer and had longer follow-up
time than the patients during the FLS period. However, the Cox
model is able to account for such an imbalance, and when cen-
soring the Cox model at 2 years’ follow-up, the associations
remained. Fourth, although the registers are reliable regarding
prescribed per-oral treatments, parenteral treatment is likely
underestimated. In Western Sweden, during 2012 to 2017, the
total yearly use of 5 mg of zoledronic acid increased from 1063
to 3958 units and of 60 mg of denosumab from 677 to
2092 units. Thus, not all units were registered in a way enabling
us to identify the individual patients, only 47% and 36%, respec-
tively. However, this does not affect the result regarding risk of
recurrent fracture. Fifth, we did not have access to reliable infor-
mation on trauma type; however, evidence shows that trauma
type does not discriminate osteoporotic from non-osteoporotic
fractures.(22) Sixth, the results are dependent on fracture risk
and guidelines in Sweden andmay not be generalizable to other
geographic settings.
Strengths of this study include the mere size of the study and
that the same methodology for data collection and analysis was
used for all hospitals and time periods. It is, to our knowledge,
the largest yet. Because an intention-to-treat analysis approach
was used, all men and women with an index fracture were
included, which minimizes the risk of selection bias. In support
of this argument, we found no substantial differences in baseline
characteristics between the FLS patients and the historic con-
trols, and the associations did not change after adjustment for
multiple covariates and comorbidity. Patient medical history
included data from primary care, which allows for a well-
documented baseline with comorbidity data and most FRAX risk
factors.(14) The lack of association between FLS and incident non-
skeletal fall injury suggests that the FLS association with risk of
recurrent fracture is due to increased use of osteoporosis medi-
cation, rather than differences in general frailty causing falls.
Also, analysis accounting for the competing risk of mortality con-
firmed the association between FLS and recurrent fracture.
Finally, the lack of associations in a nearby hospital with similar
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baseline characteristics, but without FLS, indicates lack of tempo-
ral trends in recurrent fracture.
In conclusion, FLS implementation was associated with an
18% reduction of recurrent fracture, independently of con-
founders, indicating that FLSs should be implemented as a part
of standard fracture hospital care.
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